By creator to pipelinereview.com
Novartis broadcasts discontinuation of CIRRUS-1 examine of CFZ533 (iscalimab) in kidney transplant sufferers
- Particulars
- Class: Antibodies
- Revealed on Saturday, 04 September 2021 14:01
- Hits: 207
BASEL, Switzerland I September 03, 2021 I Novartis as we speak introduced that following an interim evaluation of information from the CIRRUS-1 examine, a call has been taken to discontinue the trial.
- The evaluation indicated that CFZ533 (iscalimab)-based therapy is much less efficacious in comparison with tacrolimus-based therapy within the prevention of organ rejection in sufferers receiving a kidney transplant. Each CFZ533 and tacrolimus had been utilized in mixture with different immunosuppressive therapies (induction remedy, mycophenolate and corticosteroids).
- Examine of CFZ533 in liver transplant continues, as do research exploring CFZ533 as a possible therapy in different circumstances, similar to hidradenitis suppurativa and Sjögren’s syndrome.
Novartis is continuous to assessment the info from the CIRRUS-1 examine. As soon as full, outcomes might be shared with the broader scientific group.
SOURCE: Novartis
— to pipelinereview.com
